Montes Ana Fernández, Villarroel Paula González, Ayerbes Manuel Valladares, Gómez Juan De la Cámara, Aldana Guillermo Quintero, Tuñas Lidia Vázquez, Fernández Mercedes Salgado, Fernández Mónica Jorge
Departament of Medical Oncology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
Departament of Medical Oncology, Complexo Hospitalario Universitario de Vigo, Pontevedra, Spain.
J Cancer Res Ther. 2017 Apr-Jun;13(2):240-245. doi: 10.4103/0973-1482.181181.
Recent studies support the use of gemcitabine and nab-paclitaxel in adults with locally advanced unresectable or metastatic pancreatic adenocarcinoma although insufficient data are available on prognostic and predictive markers of response to treatment.
The objective of this study is to identify treatment response markers in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma.
This is an observational, retrospective, and multicenter study. Sociodemographic, clinical, and therapeutic data were collected. Cox regression models were applied to determine associations.
In total, 39 patients were included; 23.1% presented locally advanced pancreatic cancer and 76.9% metastatic disease. They received a mean of 6 ± 3 treatment cycles; 59% required dose reduction, 59% treatment delay, and 20.5% switched to a biweekly regimen. The overall response rate was 23% and the disease control rate was 81%. Median progression-free survival was 9 months and median overall survival (OS) was 15 months. A higher neutrophil/lymphocyte ratio (NLR) was significantly associated with lower OS. We reported Grades 1-4 nonhematological and hematological toxicities.
NLR is a useful prognostic factor for OS in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma treated with gemcitabine and nab-paclitaxel. Moreover, we suggest that a biweekly regimen is an option for certain groups of patients.
近期研究支持吉西他滨和白蛋白结合型紫杉醇用于局部晚期不可切除或转移性胰腺腺癌成人患者的治疗，尽管关于治疗反应的预后和预测标志物的数据尚不充分。
本研究旨在确定局部晚期不可切除或转移性胰腺腺癌患者的治疗反应标志物。
这是一项观察性、回顾性多中心研究。收集了社会人口统计学、临床和治疗数据。应用Cox回归模型确定相关性。
共纳入39例患者；23.1%为局部晚期胰腺癌，76.9%为转移性疾病。他们平均接受了6±3个治疗周期；59%需要减量，59%需要延迟治疗，20.5%改为双周方案。总缓解率为23%，疾病控制率为81%。无进展生存期的中位数为9个月，总生存期（OS）的中位数为15个月。较高的中性粒细胞/淋巴细胞比值（NLR）与较低的OS显著相关。我们报告了1-4级非血液学和血液学毒性。
NLR是接受吉西他滨和白蛋白结合型紫杉醇治疗的局部晚期不可切除或转移性胰腺腺癌患者OS的一个有用的预后因素。此外，我们建议双周方案是某些患者群体的一种选择。
